Share ownership Genmab A/S Nasdaq

GMAB

US3723032062

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:45:17 2026-06-16 EDT			5-day change	1st Jan Change
24.11 ^USD	-1.91%		-3.73%	-21.54%

06-15	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	62,353,067	59,493,404 ( 95.41 %)	2,859,663 ( 4.586 %)	95.41 %

Major shareholders: Genmab A/S

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 2.073 %	12,925,578	2.073 %	340 M $
AllianceBernstein LP 1.533 %	9,557,149	1.533 %	252 M $
Paradigm BioCapital Advisors LP 1.278 %	7,967,836	1.278 %	210 M $
Arrowstreet Capital LP 0.798 %	4,975,324	0.798 %	131 M $
Renaissance Technologies LLC 0.708 %	4,414,550	0.708 %	116 M $
Aperio Group LLC 0.6924 %	4,317,361	0.6924 %	114 M $
Deep Track Capital LP 0.5875 %	3,663,250	0.5875 %	96 M $
Harding Loevner LP 0.5183 %	3,231,601	0.5183 %	85 M $
Deerfield Management Co. LP (Private Equity) 0.3949 %	2,462,000	0.3949 %	65 M $
First Trust Advisors LP 0.3948 %	2,461,342	0.3948 %	65 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 5.693 %	3,549,674	5.693 %	944 M $
GENMAB A/S 4.437 %	2,766,533	4.437 %	736 M $
Jan van de Winkel 1.057 %	658,932	1.057 %	175 M $
AllianceBernstein Investments Taiwan Ltd. 0.7348 %	458,160	0.7348 %	122 M $
Nykredit Bank A/S (Investment Management) 0.5391 %	336,153	0.5391 %	89 M $
Robert W. Baird & Co., Inc. (Equity) 0.4639 %	289,270	0.4639 %	77 M $
Carmignac UK Ltd. 0.1995 %	124,369	0.1995 %	33 M $
Sjunde AP-fonden 0.166 %	103,520	0.166 %	28 M $
Svenska Handelsbanken AB (Denmark) 0.096 %	59,870	0.096 %	16 M $
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.0789 %	49,207	0.0789 %	13 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	134.49%
Others	8.38%
Genmab A/S	4.44%
Individuals	1.12%
SEI Investments Co.	0.15%
Pinnacle Financial Partners, Inc.	0.08%
Fifth Third Bancorp	0.08%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	107.19%
Bermuda	26.42%
Denmark	5.14%
Switzerland	2.07%
United Kingdom	1.83%
France	1.24%
Individuals	1.12%
Canada	1.03%
Taiwan	0.73%
Norway	0.35%
Ireland	0.32%
Germany	0.25%
Sweden	0.22%
Italy	0.12%
Finland	0.1%
Hong Kong	0.08%
Australia	0.08%
Luxembourg	0.07%
Cayman Islands	0.07%
Japan	0.06%
Belgium	0.05%
Austria	0.05%
Singapore	0.04%
Spain	0.03%
Portugal	0.02%
China	0.02%
Netherlands	0.02%
Liechtenstein	0.01%
New Zealand	0.01%
South Africa	0.01%
Mexico	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

08-05 - Earnings release - Q2 2026

More about the company